Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Other Operating Expenses (2020 - 2023)

Unicycive Therapeutics filings provide 2 years of Other Operating Expenses readings, the most recent being $1.6 million for Q3 2023.

  • On a quarterly basis, Other Operating Expenses rose 53600.0% to $1.6 million in Q3 2023 year-over-year; TTM through Jun 2024 was $1.6 million, a 108.83% increase, with the full-year FY2021 number at $8.0 million, up 852.56% from a year prior.
  • Other Operating Expenses hit $1.6 million in Q3 2023 for Unicycive Therapeutics, up from $484000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $3.5 million in Q2 2022 to a low of -$10.4 million in Q1 2023.